NirvaMed develops medical devices that provide targeted therapy solutions for reperfusion injuries, which occur when blood supply returns to tissue after a period of ischemia. Their technology aims to minimize cellular damage and improve recovery outcomes in patients experiencing these injuries.
Funding
Funding not disclosed
Founders
Product
Problem
Reperfusion injuries occur when blood supply returns to tissue after a period of ischemia, leading to cellular damage and hindering recovery. Current treatments often lack the precision needed to minimize this damage effectively.
Solution
NirvaMed develops medical devices designed to provide targeted therapy for reperfusion injuries. Their technology aims to minimize cellular damage by delivering therapeutic agents directly to the affected tissue during reperfusion. This targeted approach seeks to improve recovery outcomes by reducing inflammation and oxidative stress at the cellular level. By focusing on precision and localized treatment, NirvaMed's devices offer a potential advantage over systemic therapies, which may have broader side effects. The devices are engineered to be minimally invasive, allowing for efficient delivery of therapeutic compounds while minimizing patient discomfort.
Target Audience
The primary target audience includes hospitals, medical centers, and clinicians specializing in cardiology, neurology, and vascular surgery, where reperfusion injuries are commonly encountered.
Features
- Targeted drug delivery system for localized treatment of reperfusion injuries
- Minimally invasive design for efficient and comfortable administration
- Therapeutic agents designed to reduce inflammation and oxidative stress